prognosis, however markers that further risk-stratify intermediate groups are needed. Serum cancer antigen-125 (CA125) and human epididymis-4 (HE4) show promise as prognostic markers. The aim of this study was to evaluate the association between serum CA125, HE4 and endometrial cancer survival outcomes when stratified by molecular subgroup.

**Methodology**

Pre-treatment serum CA125 and HE4 levels were measured and endometrial tumours classified according to WHO molecular classification. The relationship between biomarkers and survival was evaluated using Kaplan-Meier analysis and multivariable cox regression.

**Results**

Overall, 327 women were included, with POLE status available for 216. Tumours were POLE-mutant (5%), p53-abnormal (11%), MMR-deficient (30%) and NSMP (54%). Median follow up was 50 months (IQR 30–60), during which 42 (13%) recurred and 71 (21%) women died. CA125≥35U/mL was independently associated with overall mortality [aHR=2.42 (95%CI:1.45–4.06), p=0.001], cancer specific death [aHR=2.00 (95%CI:1.04–3.87), p=0.04] and recurrence [aHR=2.69 (95%CI:1.38–5.27), p=0.004]. When stratified by molecular subgroup, CA125≥35U/mL and HE4≥150pmol/L were prognostic of overall survival in MMR-deficient [CA125: aHR=4.92 (95%CI:1.74–13.89), p=0.003 and HE4: aHR=4.03 (95%CI:1.34–12.11), p=0.01] and NSMP subgroups [CA125: aHR=3.72 (95%CI:1.30–10.67), p=0.001].

**Conclusion**

CA125 and HE4 may risk-stratify those at intermediate risk of recurrence and death. Evaluation in a larger population is required.

**2022-RA-1457-ESGO**

GYNECOLOGICAL CANCER DETECTION USING FOURIER-TRANSFORMED INFRA-RED SPECTROSCOPY IN URINE SAMPLES: POTENTIAL AND ACCURACY OF MACHINE LEARNING PROCESSING

Francesco Vigo, Alessandra Tozzi, Muriel Dioler, Vasiliki Kavvadias, Andre Fedier, Viola Heinzelmann-Schwarz, Tilemachos Kavvadias, Andre Fedier, University Hospital of Basel, Basel, Switzerland

10.1136/ijgc-2022-ESGO.895

**Introduction/Background**

Making an early diagnosis of cancer remains a leading cause of morbidity and mortality among gynecological cancers worldwide. The emerging technique of liquid biopsy has been proposed as a method for detecting cancer in early stage using biofluids and their properties as biomarkers.

**Methodology**

In this study, we tested the application of an artificial intelligence (AI) algorithm on infra-red spectra taken from urine samples from 84 female patients with gynecological cancer (28 breast, 32 endometrial, 24 ovarian and 10 cervical) and 200 non-tumor patients who were used as controls. The spectra were normalized, and outlier values were detected and removed using a DBSCAN algorithm. To overcome the possible problem of an unbalanced dataset, we used a SMOTE algorithm enhancing the generalization of the predictive model. The AI-model was trained and tested in classifying healthy urine samples vs different cancer types.

**Results**

The spectra were divided into training- and testing-datasets with a ratio of 80/20 randomly + 10-fold cross validation and various classifiers were put under test: decision trees, discriminant analysis, support vector machines, logistic regression and random forest, with the latter giving the best results. In the classification report Precision-, Recall-, and F1-scores varied from 0.93 to 1.00, 0.88 to 1.00 and 0.94 to 0.99 respectively.

**Conclusion**

These results confirm the reports from previous, smaller studies and show that AI-models could be useful in differentiating biofluid samples, such as urine, between patients and healthy controls. Further research is needed in order to confirm the validity of the method and to assess its potential on clinical applications.

**2022-RA-1480-ESGO**

TRANSLACOL PROJECT: DIGITAL-PCR HUMAN PAPILLOMA VIRUS (HPV) DETECTION FOR RECURRENCE PREDICTION IN EARLY CERVICAL CANCER PATIENTS WITHOUT PELVIC LYMPH NODE INVASION

Rosa Montero Macias, 2Nicolas Robillard, 3Thomas Bruneau, 2Corinada Pluvio, 4Melanie Boulihe, 4Marie-Aude Le Fere-Beloa, 1Ivana Stanekovic, 2Martina Aida Angeles, 6Eliane Mery, 2Pascal Rigollet, 6Cecile Badoius, 2Patrice Mathuevet, 2Anne Sophie Bats, 8Valerie Taly, 9David Veyer, 10Fabrice Lecuru, 1Helene Pere.

1Gynecologic and Obstetrics, Simone Veil Hospital, Eaubonne, France; 2Virology Laboratory, European Georges Pompidou Hospital, Paris, France; 3Women’s Health Institute Jose Boteba Lluisa, Hospital Clinic San Carlos, Fundacion de Investigacion del Hospital Clinico San Carlos (IDiSCS), Universidad Complutense, Madrid, Spain; 4Pathology Department, European Georges Pompidou Hospital, Paris, France; 5Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole – Institut Claudius Regaud, Toulouse, France; 6Pathology Department, Institut Universitaire du Cancer Toulouse Oncopole – Institut Claudius Regaud, Toulouse, France; 7Breast, gynecology and reconstructive surgery unit. Curie Institute, Curie Institute, Paris, France; 8Breast, gynecology and reconstructive surgery unit. Curie Institute, Curie Institute, Paris, France; 9Gynecologic and Breast Oncologic Surgery Department, European Georges Pompidou Hospital, Paris, France; 10Virology Laboratory, European Georges Pompidou Hospital, Paris, France; 11Breast, gynecology and reconstructive surgery unit. Curie Institute, Curie Institute, Paris, France

10.1136/ijgc-2022-ESGO.895

**Introduction/Background**

In early cervical cancer (ECC) patients with nodal metastasis (N+) present worse survival. However, 10–15% of patients without nodal metastasis (N0) present the same survival to N+ patients. As in cervical cancer, HPV DNA could be assimilated to tumoral DNA, we evaluate the presence of HPV DNA in pelvic Sentinel lymph nodes (SLN) after DNA extraction, HPV16 E6, HPV18 E7 and HPV33 E6 were respectively targeted and detected by ultrasensitive ddPCR as a biomarker of survival.

**Methodology**

Inclusion criteria: ECC patients who underwent pelvic SLN detection N0 in pelvic lymph nodes. Associated pelvic lymph nodes samples were available for 60 patients with HPV16, HPV18 or HPV33 positive tumours. In SLN, after DNA extraction, HPV16 E6, HPV18 E7 and HPV33 E6 gene were respectively targeted and detected by ultrasensitive ddPCR optimized on two different platforms, the RainDrop Digital PCR System (RainDance Technologies, Bio-Rad, Hercules, CA) or the Biorad system. We compare two groups according to HPV DNA in SLN: positive or negative.

**Results**

There was no difference between the negative HPV DNA SLN group and the positive HPV DNA SLN group in terms of patients and surgical-pathological characteristics, treatments and time of follow-up. Two patients in negative HPV DNA SLN group and 6 in positive HPV DNA SLN group presented recurrence and the mean time of recurrence was 10.1136/ijgc-2022-ESGO.995

Int J Gynecol Cancer: first published as 10.1136/ijgc-2022-ESGO.995 on 20 October 2022. Downloaded from http://ijgc.bmj.com/ on September 14, 2023 by guest. Protected by copyright.